NASDAQ$PBYI
Puma Biotechnology Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported a net loss due to the negative impact of COVID-19 and inventory reduction at specialty pharmacies and distributors.
Puma Biotechnology reported a net loss of $44.7 million for Q3 2021, compared to a net loss of $31.5 million for Q3 2020. Total revenue for Q3 2021 was $46.2 million, a decrease from $50.8 million in Q3 2020. The results were negatively impacted by COVID-19 and inventory reduction.
- Product revenue, net for the third quarter of 2021 was $43.4 million, compared to $49.3 million for the third quarter of 2020.
- Net loss for the third quarter of 2021 was $44.7 million, or $1.09 per share, compared to a net loss of $31.5 million, or $0.79 per share, for the third quarter of 2020.
- Net cash provided by operating activities for the third quarter of 2021 was $10.5 million, compared to $1.7 million for the third quarter of 2020.
- The company anticipates key milestones over the next 12 months, including reporting top line data from the randomized cohort of the Phase II SUMMIT trial and data from the Phase II INSIGhT trial.
Headline financials
Revenue & EPS history
Puma Biotechnology · Revenue · Quarterly
$46.2M
Revenue by segment
Puma Biotechnology · $46.2M total across 2 segments · Q3 2021
- Product Revenue, Net$43.4M—93.9%
- Royalty Revenue$2.8M+86.7%6.1%
Forward guidance
Puma Biotechnology anticipates several key milestones over the next 12 months.
Tailwinds
- Reporting top line data from the randomized cohort of the Phase II SUMMIT trial of neratinib in hormone receptor positive breast cancer that has a HER2 mutation (Q4 2021).
- Reporting data from the Phase II INSIGhT trial of neratinib in patients with glioblastoma at the Society of NeuroOncology (SNO) Annual Meeting (Q4 2021).
- Conducting a Type C meeting with the FDA to discuss potential for accelerated approval of neratinib in HER2-mutated hormone receptor positive breast cancer (Q4 2021).
- Reporting data from the Phase II TBCRC-022 trial of the combination of Kadcyla® plus neratinib in patients with HER2-positive breast cancer with brain metastases who have previously been treated with Kadcyla (H1 2022).
- Reporting Phase II data from the SUMMIT trial of neratinib in non-small cell lung cancer patients with EGFR exon 18 mutations (H1 2022).
Headwinds
- The company's operating results continued to be negatively impacted by the effects of COVID-19.
- Net revenue for the quarter was negatively impacted by approximately $3.5 million due to inventory reduction at specialty pharmacies and specialty distributors.
- Conducting a meeting with the FDA to discuss the potential for an accelerated approval pathway for neratinib in non-small cell lung cancer patients with EGFR exon 18 mutations who have previously been treated with an EGFR tyrosine kinase inhibitor (2022).
- Reporting Phase II data from the SUMMIT trial of neratinib in cervical cancer patients with HER2 mutations (H1 2022).
- Receiving regulatory decisions for the extended adjuvant HER2-positive early stage breast cancer indication in additional countries (Q4 2021/H1 2022).
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-1.6%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+4.4%
Avg return
30 days after
47%
21 / 45 earnings
Positive
+36.4%
Q4 2018
Best reaction
-45.8%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -6.0% | -5.8% | |
| Q4 2025 | -25.1% | -15.8% | -20.0% | |
| Q3 2025 | +21.8% | +1.8% | +8.2% | |
| Q1 2025 | -4.6% | -5.5% | +21.2% | |
| Q4 2024 | +19.7% | +18.4% | +5.0% | |
| Q3 2024 | -5.9% | +4.9% | +2.0% | |
| Q2 2024 | +6.7% | +12.3% | -30.4% | |
| Q1 2024 | -1.8% | -4.0% | -22.2% | |
| Q4 2023 | -10.8% | -21.5% | -19.7% | |
| Q3 2023 | +4.9% | +9.4% | +41.5% | |
| Q2 2023 | +5.8% | +13.3% | +2.5% | |
| Q1 2023 | +19.8% | +19.4% | +35.0% | |
| Q4 2022 | -20.1% | -26.6% | -23.1% | |
| Q3 2022 | +25.5% | +50.9% | +106.0% | |
| Q2 2022 | +23.5% | +17.4% | -17.0% | |
| Q1 2022 | -19.1% | -26.0% | -4.9% | |
| Q4 2021 | +13.5% | +25.7% | +34.2% | |
| Q3 2021 | -39.1% | -42.2% | -54.6% | |
| Q2 2021 | +3.6% | +3.6% | +7.9% | |
| Q1 2021 | +1.6% | -0.8% | +17.0% | |
| Q4 2020 | -11.9% | -11.9% | -12.6% | |
| Q3 2020 | -11.0% | +1.3% | +31.8% | |
| Q2 2020 | -5.7% | -7.9% | -11.6% | |
| Q1 2020 | +11.2% | +23.1% | +6.4% | |
| Q4 2019 | -2.4% | -18.8% | -43.9% | |
| Q3 2019 | +4.2% | +18.0% | +9.1% | |
| Q2 2019 | +26.7% | +25.8% | +22.1% | |
| Q1 2019 | -38.6% | -41.5% | -53.9% | |
| Q4 2018 | +36.4% | +35.3% | +35.9% | |
| Q3 2018 | -45.8% | -39.5% | -37.3% | |
| Q2 2018 | -7.5% | -7.1% | -2.1% | |
| Q1 2018 | -19.0% | -18.9% | -24.3% | |
| Q4 2017 | +8.7% | +16.7% | +4.1% | |
| Q3 2017 | -22.2% | -24.3% | -23.9% | |
| Q2 2017 | -11.6% | -1.7% | +28.0% | |
| Q1 2017 | +1.5% | +4.3% | +163.9% | |
| Q4 2016 | -10.6% | -8.3% | +1.4% | |
| Q3 2016 | +21.3% | -0.5% | -9.4% | |
| Q3 2015 | -9.6% | — | — | |
| Q1 2015 | +2.0% | — | — | |
| Q4 2014 | -3.3% | — | — | |
| Q1 2013 | +3.7% | — | — | |
| Q3 2012 | -6.4% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +1.9% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro